Introducing Sofosbuvir/Velpatasvir + Ribavirin as a Generic Retreatment Regimen for Hepatitis C: Evaluation of a Government Program in Rwanda.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 39878504.
- Also identified by DOI 10.1093/cid/ciae637.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Sofosbuvir/velpatasvir/voxilaprevir is recommended for hepatitis C virus (HCV) retreatment in those who fail initial treatment but is unavailable in resource-limited settings. We describe a government sofosbuvir/velpatasvir + ribavirin (SOF/VEL + RBV) × 24 weeks retreatment program in Rwanda (November 2021-October 2022). Of 231 participants, 174 were cured (75.3% intention-to-treat analysis). SOF/VEL + RBV may be considered for HCV retreatment in resource-limited settings.
Medical subject headings
- Sofosbuvir
- Antiviral Agents
- Heterocyclic Compounds, 4 or More Rings
- Ribavirin
- Carbamates
- Hepatitis C, Chronic
- Hepatitis C